Heidelberg Pharma AG (WBO:HPHA) Shares Outstanding (EOP): 46.78 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:HPHA Heidelberg Pharma AG WBO:HPHA
10 GF Score
Price €2.55
GF Value €2.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Shares Outstanding (EOP)?

Heidelberg Pharma AG WBO:HPHA 10 Shares Outstanding (EOP) is 46.78 Mil as of May. 2026. GuruFocus rates WBO:HPHA with a GF Score™ of 10/100 and a GF Value™ of €2.87 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Heidelberg Pharma AG's shares outstanding for the quarter that ended in May. 2026 was 46.78 Mil.

Heidelberg Pharma AG's quarterly shares outstanding stayed the same from Feb. 2026 (46.78 Mil) to May. 2026 (46.78 Mil).

Heidelberg Pharma AG's annual shares outstanding increased from Nov. 2024 (46.61 Mil) to Nov. 2025 (46.78 Mil). It means Heidelberg Pharma AG issued new shares from Nov. 2024 to Nov. 2025 .


Heidelberg Pharma AG  (WBO:HPHA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Heidelberg Pharma AG Shares Outstanding (EOP) Related Terms


Heidelberg Pharma AG Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Shares Outstanding (EOP) Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.18 46.58 46.61 46.61 46.78

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.61 46.78 46.78 46.78 46.78

WBO:HPHA vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Heidelberg Pharma AG's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Shares Outstanding (EOP) falls into.


WBO:HPHA
10GF Score
Heidelberg Pharma AG WBO:HPHA
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 46.78 Mil mean?
Heidelberg Pharma AG (WBO:HPHA) has a Shares Outstanding (EOP) of 46.78 Mil as of May. 2026. The total shares a company has outstanding, at period-end. View historical data on Heidelberg Pharma AG and its competitors.
Is Heidelberg Pharma AG's Shares Outstanding (EOP) too high?
Heidelberg Pharma AG's current Shares Outstanding (EOP) is 46.78 Mil. Overall, Heidelberg Pharma AG has a GF Score™ of 10/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Shares Outstanding (EOP) compare to VRTX and REGN?
Heidelberg Pharma AG's Shares Outstanding (EOP) of 46.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current Shares Outstanding (EOP) is 46.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current Shares Outstanding (EOP) is 46.78 Mil. Heidelberg Pharma AG's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current Shares Outstanding (EOP) is 46.78 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for WBO:HPHA:

  • Shares Outstanding (EOP): 46.78 Mil
  • GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Germany
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score

Get the complete analysis for WBO:HPHA

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.87
GF Value